
SomaLogic
SomaLogic is fostering the discovery of effective and safer treatments for patients while empowering more accurate diagnosis, prevention and treatment of disease through the next generation of proteomics.
Latest SomaLogic Content

Product News
OncoHost To Present Proteomics-Based Predictive Biomarker for Immune-Related Adverse Events in NSCLC Patients
Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

Webinar
Using Plasma Proteomics To Understand Alzheimer’s and Other Brain Diseases
On-Demand
Dr. Walker will discuss how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.

Infographic
High-Throughput Protein Profiling: Discover New Disease Biomarkers
While most protein assays excel in one or two areas, the SomaScan Assay is the first and only platform that can measure 7,000 proteins from a 55-µL sample – covering more biological pathways than any other proteomic assay.

Whitepaper
Discovery of Blood-Based Biomarkers in Neurodegenerative Diseases
The SomaScan Assay is an ideal high throughput platform for identifying proteins that may be involved in disease pathology, as it offers a highly sensitive method of quantifying proteins in different biologic fluids such as serum, plasma, urine and cerebrospinal fluid.

App Note / Case Study
Discover Novel Biomarkers for Drug Discovery and Clinical Diagnostics
Developed for performance in human serum and plasma, the SomaScan Assay v4.1 can measure approximately 7,000 unique human protein analytes in small volumes of biological samples.

Product News
OncoHost To Present Proteomics-Based Biomarker Model for Clinical Benefit to Immunotherapy in NSCLC Patients at SITC 2022
OncoHost has developed a novel predictive model for clinical benefit of immune checkpoint inhibitor in non-small cell lung cancer patients.

Video
Using the SomaSignal® Tests for Pre-Analytical Variation Assessments With Joe Gogain
In this Teach Me in 10 episode, Joe Gogain, director of clinical research and development at SomaLogic, will be discussing SomaSignal™ Tests.

Podcast
Proteomics Coming of Age: Recent Advances and Predictions for the Future
In this episode of Opinionated Science, Lucy Lawrence is joined by Dr. Steve Williams, the chief medical officer at SomaLogic.

Product News
SomaLogic Announces License Agreement With OncoHost for the Development of Precision Cancer Diagnostics
SomaLogic has announced it has signed a licensing agreement with OncoHost.
Advertisement